Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company reported a significant increase in net profit for Q1 2025, achieving a net profit of 310 million yuan, a year-on-year increase of 41.3%, despite a revenue decline of 4.8% to 3.45 billion yuan [5][6] - The improvement in gross margin is attributed to enhanced production efficiency and a shift in channel structure, with the gross margin reaching 34.3%, up 4.3 percentage points year-on-year [7][8] - The company is actively optimizing its store layout while increasing the number of high-margin direct sales channel stores [6][8] Summary by Sections Financial Performance - Q1 2025 revenue breakdown by product: cabinets 980 million yuan (-8.5%), wardrobes 1.8 billion yuan (-5.6%), bathrooms 220 million yuan (+9.7%), wooden doors 220 million yuan (+1.0%) [6] - Revenue by channel: direct sales 160 million yuan (+10.2%), distribution 2.59 billion yuan (-1.3%), bulk sales 500 million yuan (-28.6%) [6] Profitability Metrics - Q1 2025 gross margin by product: cabinets 29.7% (+4.1 pcts), wardrobes 39.8% (+4.2 pcts), bathrooms 24.1% (+2.8 pcts), wooden doors 21.2% (+6.2 pcts) [7] - Q1 2025 gross margin by channel: direct sales 55.6% (+2.5 pcts), distribution 35.4% (+3.5 pcts), bulk sales 17.4% (+1.5 pcts) [7] Future Projections - The company’s net profit forecasts for 2025-2027 have been slightly raised to 2.84 billion yuan, 3.20 billion yuan, and 3.52 billion yuan respectively, reflecting increases of 3%, 5%, and 6% [8][9] - Projected EPS for 2025-2027 are 4.67 yuan, 5.26 yuan, and 5.78 yuan, with corresponding P/E ratios of 14, 12, and 11 times [8][9]

Core Viewpoint - The company reported a revenue of 3.84 billion yuan for 2024, representing a year-on-year increase of 9.6%, and a net profit attributable to shareholders of 270 million yuan, up 266.9% year-on-year, indicating strong financial performance driven by the rapid growth of its cream product line and effective channel transformation strategies [1] Financial Performance - For 2024, the company achieved a revenue of 3.84 billion yuan, with a net profit of 270 million yuan and a non-recurring net profit of 250 million yuan, reflecting increases of 9.6%, 266.9%, and 108.2% year-on-year respectively [1] - In Q1 2025, the company reported a revenue of 1.05 billion yuan, a year-on-year increase of 14.1%, and a net profit of 90 million yuan, up 15.1% year-on-year, indicating continued growth momentum [1] - The company's non-recurring net profit margin for 2024 was 6.6%, an increase of 3.1 percentage points year-on-year, with a gross margin of 31.5% [2] Product and Channel Performance - The revenue growth by product category for 2024 showed a decline in frozen baking and sauces, while cream products surged by 61.8%, indicating a strong demand for UHT cream products [1] - The company has over 1,800 distributors and more than 600 direct sales customers, with revenue from distribution channels, supermarkets, and new retail channels showing varied growth rates [1] - The company is expected to continue benefiting from the ongoing trend of cream product sales and channel transformations, particularly in membership stores and supermarkets [1] Cost Management - The company improved its cost structure, with a sales expense ratio of 12.1% for 2024, down 1.4 percentage points year-on-year, attributed to refined management practices [2] - The management expense ratio for 2024 was 6.7%, a decrease of 2.9 percentage points year-on-year, reflecting strict control over executive expenses [2] Future Outlook - Revenue projections for 2025 to 2027 are estimated at 4.38 billion, 5.05 billion, and 5.86 billion yuan, with corresponding year-on-year growth rates of 14.2%, 15.3%, and 16.1% [3] - The net profit attributable to shareholders is expected to reach 320 million, 370 million, and 430 million yuan for the same period, with growth rates of 18.3%, 15.8%, and 17.5% respectively [3] - The company is positioned to maintain a strong growth trajectory in the baking sector, supported by its product strength and supply chain capabilities [3]

公司研究 证 券 研 究 报 告 立高食品（300973）2024 年报及 2025 年一季报点评 强推（维持） 效率进阶，再超预期 事项： 公司发布 2024 年报，24 年实现总营收 38.35 亿元，同比+9.6%；归母净利润 2.68 亿元，同比+266.9%；24Q4 实现营收 11.18 亿元，同比+22.0%；归母净利 润 0.65 亿元，实现扭亏为盈；25Q1 实现营收 10.46 亿元，同比+14.1%；归母 净利润 0.88 亿元，同比+15.1%。 评论： 休闲食品 2025 年 4 月 29 日 目标价：49.5 元 当前价：37.18 元 华创证券研究所 证券分析师：欧阳予 邮箱：ouyangyu@hcyjs.com 执业编号：S0360520070001 证券分析师：董广阳 电话：021-20572598 邮箱：dongguangyang@hcyjs.com 执业编号：S0360518040001 联系人：严文炀 邮箱：yanwenyang@hcyjs.com 公司基本数据 | 总股本(万股) | 16,934.05 | | --- | --- | | 已上市流通股(万股) | 1 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Viewpoints - Despite short-term performance pressure due to channel transformation, the company is expected to benefit from product volume potential under the empowerment of China Resources Sanjiu, with an overall positive operational trend anticipated [4]. - The company reported Q1 2025 revenue of 1.61 billion RMB, a year-on-year decrease of 16.5%, and a net profit attributable to shareholders of 90 million RMB, down 31.1% year-on-year [2]. - The company is focusing on brand development and product volume growth, particularly with its strategic products like "Kunzhong Medicine 1381" and "777 Xuesaitong Soft Capsules" [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved revenue of 1.61 billion RMB, a decrease of 16.5% year-on-year, and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The decline in performance is attributed to multiple factors, including channel transformation and the impact of national Chinese medicine procurement expansion [2]. Operational Analysis - The company is in the final phase of integration with China Resources Sanjiu, with further breakthroughs in channel transformation expected to enhance terminal coverage and performance in Q2 2025 [2]. - The focus on brand positioning as a "leading national medicine" and the emphasis on terminal coverage and sales are expected to drive healthy growth for core products [3]. Profit Forecast and Valuation - The company’s net profit forecasts for 2025, 2026, and 2027 are 740 million RMB, 893 million RMB, and 1.072 billion RMB, respectively, with year-on-year growth rates of 14%, 21%, and 20% [4]. - The expected earnings per share (EPS) for the same years are 0.98 RMB, 1.18 RMB, and 1.42 RMB, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 times [4].

盈利预测：我们预计公司2025-2027 年分别实现营业收入20.22/22.72/25.39 亿元，同比 +9.03%/+12.35%/+11.76%，分别实现归母净利润1.57/1.87/2.20 亿元，同比+6.46%/+18.94%/+17.99%， EPS 分别为0.36/0.43/0.50 元/股，对应PE 为39X/33X/28X，维持"推荐"评级。 风险提示：食品安全问题，原材料价格波动风险，新产品拓展不及预期，渠道开拓不及预期、改革不及 预期等 25Q1 公司实现毛利率/归母净利率分别31.38%/7.63%，分别同比-7.32/-7.27pct。公司毛利率同比大幅下 滑，主要系：1）受部分水果原料减产及供需关系的影响，部分原料成本有所上涨；2）公司积极开拓零 食专营连锁渠道及原料销售业务，该渠道及业务毛利率相对偏低。费用端看，25Q1销售/管理/财务/研 发费用率分别13.09%/6.84%/0.26%/0.15%，分别同比+0.14/+1.53/+0.37/-0.03pct。从绝对值看，25Q1 公 司销售费用已实现同比环比减少，公司将继续进行渠道精耕和精细化管理，根据不同市场情况制定不 ...

1Q25 业绩基本符合我们预期 今年以来公司将推进多项调整政策以应对渠道变革及白热化价格竞争，线下公司将1）重塑基础营养品 价值链，通过低客单、低日服的方式与连锁药店合作打造多款单品以推动销量增长，1Q 推出的钙DK 产品表现好于预期，2Q 有望继续推出维生素、益生菌等产品；2）多模式专业化运作驱动重功能、刚需 品增长，如蛋白粉等；3）推出专业化、高净值的高端化产品如专供药线渠道的批文产品，提升复购。 线上渠道方面，公司有望透过高端产品升级，如双金标藻油、高纯极地鱼油等展开差异化，及基础营养 素的单品推广，同时公司将启动主品牌的抖音直播间搭建，提升品牌认知。我们预计以上措施有望自 2Q 起贡献额外收入增量，我们判断公司挑战最大的时期已经过去，未来收入及利润有望迎来逐季改 善。 盈利预测与估值 考虑线下渠道压力，下调25/26 年盈利预测6%/6%至8.3/9.8 亿元。公司当前交易在22.5/19.0 倍25/26 年 P/E；但考虑市场估值上行，维持目标价12.6 元，对应26.0/21.9 倍25/26 年P/E 和15.4%股价上行空间； 考虑保健品赛道长期空间广阔，维持跑赢行业评级。 风险 线上竞争加 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4]. Core Viewpoints - The company experienced a revenue decline of 16.5% year-on-year in Q1 2025, with total revenue reaching 1.61 billion RMB and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The integration with China Resources Sanjiu is in its final phase, and while short-term performance is under pressure due to channel transformation, there are expectations for improvement as new procurement standards are implemented in Q2 [2][4]. - The company is focusing on brand development and enhancing terminal coverage, particularly for key products like "Kunzhong Medicine 1381" and "777 Xuesaitong Soft Capsules," which are expected to see healthy growth [3]. Summary by Sections Performance Analysis - In Q1 2025, the company reported a revenue of 1.61 billion RMB, a decrease of 16.5% year-on-year, and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The decline is attributed to multiple factors, including channel transformation and the ongoing integration with China Resources Sanjiu [2]. Brand Development - The company is committed to its brand strategy, focusing on key products to strengthen its position as a leading national medicine brand [3]. - The launch of new packaging for "777 Xuesaitong" is expected to enhance brand recognition and drive sales growth [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 740 million RMB, 893 million RMB, and 1.072 billion RMB for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 14%, 21%, and 20% [4]. - The earnings per share (EPS) are expected to be 0.98 RMB, 1.18 RMB, and 1.42 RMB for the same years, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 [4].

Group 1: Company Performance and Sales Outlook - The company achieved growth in both domestic and international sales in Q1 2025, supported by the government's trade-in policy and local government cooperation [2] - The company aims to maintain better-than-industry performance in domestic sales and stable growth in international sales through continuous product innovation and channel transformation [2] Group 2: Impact of Tariffs and Competition - The high tariffs imposed by the U.S. on Chinese exports have a minimal impact on the company due to its low exposure in the North American market and flexible capacity allocation through its Vietnam base [3] - To maintain profit margins amid intense competition, the company focuses on resource investment in sales growth and product innovation, while implementing strict cost management [3] Group 3: New Product Categories and Innovations - The company evaluates new product categories based on market capacity and technological iteration potential, with plans to enter segments like desktop water purifiers and tea machines [4] - In 2024, the company launched innovative products such as the IH rice cooker and titanium non-stick frying pan in its traditional strong categories [4] Group 4: Dividend Policy and Online Sales Channels - The company has a high dividend payout ratio and plans future dividends based on capital expenditure and cash flow conditions [4] - Online sales channels, particularly traditional e-commerce platforms like Tmall, JD.com, and Pinduoduo, remain stable contributors to sales, while social e-commerce platforms are experiencing rapid growth [4]

Investment Rating - The investment rating for the company is "Recommended" [4][13]. Core Views - The company reported a revenue of 9.19 billion yuan in 2024, a year-on-year increase of 1.4%, but the net profit attributable to shareholders decreased by 15.1% to 590 million yuan due to increased impairment losses [4][7]. - In Q1 2025, the company achieved a revenue of 1.27 billion yuan, a year-on-year decline of 14.3%, while the net profit attributable to shareholders increased by 14.2% to 100 million yuan [4][7]. - The company plans to distribute a cash dividend of 3.2 yuan per 10 shares (tax included) for 2024 [4]. Summary by Sections Financial Performance - In 2024, the company experienced a revenue of 91.9 billion yuan, with a gross margin of 18.1%, slightly down by 0.3 percentage points [7]. - The net profit for 2024 was 5.9 billion yuan, reflecting a significant decline due to increased impairment losses totaling 430 million yuan [7][9]. - The company’s revenue is projected to grow to 99.3 billion yuan in 2025, with a net profit of 7.5 billion yuan expected for 2025 [10][11]. Business Segments - The decorative materials segment generated 74.0 billion yuan in revenue, up 7.99% year-on-year, with a gross margin of 17.04% [7]. - The custom home segment reported a revenue of 17.2 billion yuan, down 18.73%, primarily due to challenges in the engineering business [7]. - The company has significantly expanded its rural store network, with 1,413 new stores established, bringing the total to 5,522 [7]. Cash Flow and Financial Ratios - The net cash flow from operating activities for 2024 was 1.15 billion yuan, down from 1.91 billion yuan in the previous year [9][12]. - The company’s total assets are projected to reach 6.37 billion yuan in 2025, with a debt-to-asset ratio of 46.1% [10][11]. - The return on equity (ROE) is expected to be 22.7% in 2025, indicating strong profitability [11]. Market Outlook - The domestic engineered wood market is expected to grow, supported by the demand for home renovations [9]. - The company has established strong brand barriers and is focusing on channel transformation, particularly in rural markets [9].